ID: MRFR/HC/6223-CR | April 2019 | Region: Global | 153 pages
The global prils market is predicted to grow with a 4.3% CAGR, and the market size will expand up to USD 2591.5 million by the year 2018-2023. The prils market comprises of active pharmaceutical ingredients (APIs). These are active ingredients are crucial for the manufacturing of medicines as they contain therapeutic properties. There are different types of APIs used in biotech, nutritional and pharmaceuticals industries for the development of drugs and medicines. The factors responsible for the growth of the prils market are increasing number of heart disease, hypertension, kidney failures, and the older population.
The outbreak of the COVID-19 pandemic has primarily affected the pharmaceutical and biotechnological industry. The global prils market observed massive demand for the products to treat high blood pressure, hypertension, chronic heart diseases, kidney disorders and others. The virus had a severe impact on the patients who were already suffering from these diseases. Due to this reason, the market observed a surge in the demands across the world. Also, several countries joined hands to overcome these problems by manufacturing efficient drugs.
The global prils market is growing at a rapid speed. Several healthcare companies are trying to develop efficient drugs, which are one of the crucial factors driving the market. Other significant factors such as increasing cases of high blood pressure, hypertension, kidney diseases, and sedentary lifestyle are major market drivers.
There are several companies trying to develop sustainable and efficient drugs for patients suffering from chronic diseases such as hypertension, high blood pressure, kidney-related diseases. Factors such as high costs of drugs, growth of several companies that provide fake medications, complexities to get approval from the regulatory bodies of different countries is expected to hinder the growth of the global prils market.
The complex process may take few years to get the approval for tests and manufacturing of the product. In this way, the production may take a much more extended period to finally arrive in the market and consumers. Production of efficient drugs and getting approval from concerned authorities is a challenging task for pharmaceutical companies will be a challenging task.
As per reports by Centres for Disease Control and Prevention 2016, about 35 million people in America had high blood pressure. Also, the Massachusetts Medical Society found that the number of patients having systolic blood pressure spiked up to 874 million from 442 million between the years 1995-2015. In this way, there are many patients around the world who are suffering from chronic diseases such as kidney failures due to consumption of alcohol an unhealthy lifestyle. The surge in the cases of cardiovascular diseases possesses a great opportunity for the pharmaceutical and biotech companies to develop new drugs and grow their business estimate in the forecast period. Several companies are competing with each other to make efficient product and expand their business. The spike in the number of patients will be an excellent opportunity for the pharmaceutical and biotechnological companies.
Cumulative Growth Analysis
The global prils market is estimated to grow at a CAGR rate of 4.3% during the forecast year 2018-2023. It is expected that the market will reach up to USD 2591.5 million during the forecast period year 2018-2023. The active APIs such as Ramipril, Quinapril, Benazepril and Cilazapril are effective ingredient use in the therapeutics for hypertension, high blood pressure, and other chronic diseases. The market is predicted to have a substantial growth across the world. Developed countries like the U.S. and Canada are equipped with the best healthcare facilities causing a substantial share in the prils market.
Value Chain Analysis
In future years, the value of active pharmaceutical ingredients such as Ramipril, Benazepril, Quinapril and Cilazapril will substantially increase. Increasing cases of such chronic diseases are primarily responsible for the growth of prils market. According to a recent study, the number of patients suffering from blood pressure has increased over the past years. So, the sedentary lifestyle of people, such as consumption of alcohol and other drugs, is also increasing which will eventually increase the value of global prils market.
The global prils market is segmented into Quinapril, Ramipril, Benazepril and Cilazapril. These are some active pharmaceutical agents generally prescribed as a cure for hypertension based upon different concentration.
Ramipril is an Angiotensin-Converting Enzyme (ACE), primarily preferred to treat hypertension. Ramipril is also used to reduce risks of heart attack, strokes, kidney disorders, and regulate blood vessels and normalise blood flow. It is expected that Ramipril will dominate the prils market because it is prescribed mainly for patients having heart problems and gets easily binded to ACE in the vascular tissue and reduces hypertension. Also, there are other similar APIs prescribed to treat chronic diseases, such as quinapril, cilazapril and benazepril.
By Application, the prils market is classified into heart failure, kidney disorders, heart failures, etc.
Geographically, the global prils market is segmented into America, Asia-Pacific, Europe, The Middle East and African Region.
The global prils market for the Americas region is further segmented into North and South America. The North American region comprises the United States of America and Canada. North and Latin America primarily dominate the prils market due to the increasing rate of technological advancements in the therapeutics industry and a spike in cases of neurological disorders and chronic diseases. Pharmaceutical industries largely are considered the best and have observed rapid growth than other countries.
The European region is estimated to have a significant growth as it is the second-largest market to generate revenue in the global prils market. Several initiatives are constantly taken to support the growth of generic drug along with reimbursements and pricing.
Asia-Pacific region has observed a substantial growth in the recent past years. Developing nations such as India and China are expected to largely contribute to the growth of the prils market in a positive way. Increasing numbers of pharmaceutical and biotechnological companies, healthcare centres will help the market to rise.
A slower growth rate is expected in the Middle East and the African region due to the lack of good healthcare centres, technological advancements, etc.
Companies such as Lupin, Pfizer, Mylan N.V., F. Hoffman-L Roche, Novartis AG are introducing new products, acquisitions, mergers, collaborations, joint ventures to improve this business and technological growth. For example, Lupin Limited acquired Novel Laboratories and Gavis Pharmaceuticals LLC for about $880 million. This acquisition with Gavis will bring highly skilled researchers to Lupin with its own Research and Development centre.
Here is the list of competitive companies in the global prils market-
The global prils market gives different information and insights about the changes, demands, and developments during the forecast. Information about the market drivers, restraints, challenges and competitive landscape are provided. It also offers an analytical representation of the market trends, opportunities, investments in research and development and present pharmaceutical and biotechnological companies. The information provided in this report is collected from primary and secondary sources.
Report Score and Segmentation
By Geographical Region
Frequently Asked Questions (FAQ) :
Prils market is projected to grow at a 4.3% CAGR between 2020-2027.
The Americas is expected to dominate the prils market.
Prils market is predicted to touch USD 2,591.5 million by 2023.
Prils are widely used for chronic kidney disorders, heart failure, and hypertension.
Rise in counterfeit drugs may limit the prils market growth.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.